Antibody treatment in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Antibody therapy is a cornerstone in multiple myeloma (MM) treatment.
• Key classes include monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies.
• These therapies target specific myeloma cell markers.

Purpose of the Study:

• To review the evolving role of antibody therapy in MM.
• To describe the distinct adverse event profiles of different antibody drug classes.
• To provide guidance on integrating antibody therapy into clinical practice.

Main Methods:

• Review of current literature on antibody therapies in MM.
• Analysis of clinical trial data and real-world evidence.
• Synthesis of information on drug mechanisms, efficacy, and safety.

Main Results:

• Anti-CD38 and anti-SLAMF7 monoclonal antibodies are established treatments for relapsed/refractory MM.
• Daratumumab is now crucial for newly diagnosed MM, with a subcutaneous option available.
• BCMA-targeted antibody-drug conjugates and bispecific antibodies offer new hope for heavily pretreated patients.

Conclusions:

• Antibody therapies have transformed MM treatment paradigms.
• Understanding unique adverse events is crucial for safe and effective use.
• Strategic incorporation of these agents optimizes patient outcomes in MM.